Where next for Acacia Pharma on positive PhIII PONV data?
This article was originally published in Scrip
Executive Summary
Private UK company Acacia Pharma is hoping to return dopamine antagonists to the arsenal of drugs available for post-operative nausea and vomiting (PONV) following positive top-line results from two Phase III studies of its lead product APD421.